Moderna Coronavirus Vaccine: Moderna has been leading the efforts in making a vaccine against Coronavirus and had already announced that its Phase 1 tests were a success but those were not peer reviewed. In the latest peer-reviewed data in New England Journal of Medicine, it was demonstrated that their vaccination with mRNA-1273 elicits a robust immune response across all dose levels and clearly support the choice of 100 µg in a prime and boost regimen as the optimal dose for the Phase III study
The chart below shows how anti-bodies are increasing over a 35 day period. In case of 100 µg, it increases from 131 on day 1 to 781399 on day 36.
Moderna will commence larger sample trials in Phase III study of mRNA-1273 during the last week of this month to demonstrate the vaccine’s ability to significantly reduce the risk of COVID-19 disease. Phase III trials will enroll 30000 participants and and will include a Placebo group as well. Phase III is likely to be over by middle to end of September . The study will be stopped early if the side effects of the new drug are too severe or if one group has much better results. Phase III clinical trials are often needed before the FDA will approve the use of a new drug for the general public.
It is likely Moderna will have a drug ready by December this year and start selling early next year.
Dr. Anthony Fauci, the United States's top infectious disease expert has predicted that scientists will be able to create a vaccine by the year end or early next year